Patients with atopic dermatitis had an increased risk of COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

New data suggest that, in recent years, US cancer incidence has generally remained stable, and the rate of cancer deaths has generally decreased.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Increasing physical activity is associated with a lower amyloid burden, suggesting benefits for neurological aging.

The observed prevalence of depressive symptoms increased after vs before 2020 among US adults, especially those aged less than 44 years.

The incidence and prevalence of atopic dermatitis among older adults increased from 1990 to 2021, although age-standardized rates decreased.

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

The use of autonomous TBP and dermoscopic device is comparable in quality to that of standard manual imaging, though it may have greater time efficiency.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Phototherapy with topical antioxidants is the most effective combination for vitiligo, followed by corticosteroids and calcineurin inhibitors.

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

The HHS will require all new vaccines to undergo placebo-controlled trials, likely slowing down approvals and decreasing access.